论文部分内容阅读
应用肾脏病调查表和Ｋａｒｎｏｆｓｋｙ指数等方法，前瞻性研究了重组人红细胞生成素（ｒＨｕＥＰＯ）对１０４例尿毒症患者生活质量的影响，结果显示，治疗３～５个月所有患者贫血均有明显纠正，Ｈｃｔ维持在３０％～３５％，生活质量有显著改善（Ｐ＜０．００１）；家庭透析显著优于住院透析（Ｐ＜０．０１），青壮年组显著高于老年组（Ｐ＜０．０５）；腹透患者体力改善情况显著优于血透患者（Ｐ＜０．０５）．高血压、血栓形成等副作用明显影响生活质量的提高，尤其在血透和老年患者中，研究表明，ｒＨｕＥＰＯ在纠正尿毒症患者贫血的同时能明显提高患者生活质量，治疗过程中应及时防治高血压等副作用。
Using the renal disease questionnaire and Karnofsky index and other methods, a prospective study of recombinant human erythropoietin (rHuEPO) on the quality of life of 104 patients with uremia, the results showed that all patients in 3 to 5 months of treatment were significantly corrected anemia (P <0.001). The family dialysis was significantly better than hospital dialysis (P <0.01), and the young and middle-aged group was significantly higher than the old group (P <0) .05). The improvement of physical strength in patients with peritoneal dialysis was significantly better than that in hemodialysis patients (P <0.05). Hypertension, thrombosis and other side effects significantly affect the quality of life, especially in hemodialysis and elderly patients, studies have shown that rHuEPO in patients with anemia correct uremia can significantly improve the quality of life of patients, the treatment process should be timely prevention and treatment of hypertension Other side effects.